Want to see CH:KURN full AI Analyst Report?
Top Page
Kuros Biosciences
(KURN)
Select Model
Select Model
Rating:63Neutral
Price Target:
CHF21.00
▼(-1.96% Downside)
Action:Reiterated
Date:08/19/26
The score is driven primarily by solid financial progress (rapid revenue scaling, high gross margins, and low leverage) and a positive earnings-call outlook with strong H1 results and clear mid-term targets. These positives are tempered by weak cash-flow quality, a mixed technical trend versus the 200-day average, and a high P/E valuation that increases sensitivity to any execution or margin setbacks.
Positive Factors
Rapid revenue growth and profitability inflection
Strong sales growth combined with a first half-year profit demonstrates meaningful commercial scaling and improving operating leverage. If execution continues, the expanding revenue base can support reinvestment, strengthen market position, and improve earnings durability over the next several quarters.
Negative Factors
Weak cash conversion and working-capital pressure
Cash generation has lagged accounting earnings, with operating and free cash flow turning negative after positive prior-year figures. Elevated receivables and continued investment can increase funding sensitivity, limiting flexibility if conversion does not improve as the business scales.
Read all positive and negative factors
Positive Factors
Negative Factors
Rapid revenue growth and profitability inflection
Strong sales growth combined with a first half-year profit demonstrates meaningful commercial scaling and improving operating leverage. If execution continues, the expanding revenue base can support reinvestment, strengthen market position, and improve earnings durability over the next several quarters.
Read all positive factors
Kuros Biosciences (KURN) vs. iShares MSCI Switzerland ETF (EWL)
Market Cap
CHF791.16M
Dividend YieldN/A
Average Volume (3M)234.60K
Price to Earnings (P/E)109.9
Beta (1Y)1.20
Revenue Growth40.91%
EPS GrowthN/A
CountryCH
Employees213
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)0.18
Shares Outstanding39,756,700
10 Day Avg. Volume317,979
30 Day Avg. Volume234,605
Financial Highlights & Ratios
PEG Ratio-3.21
Price to Book (P/B)15.78
Price to Sales (P/S)8.71
P/FCF Ratio-439.50
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
CHF33.00Price Target Upside54.06% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)0.32
Revenue Forecast (FY)CHF204.27M
Kuros Biosciences Business Overview & Revenue Model
Company Description
Kuros Biosciences AG functions as a biopharmaceutical enterprise, dedicated to both the development and market introduction of advanced therapeutic solutions for tissue regeneration and bone repair. Its operations span across the United States, th...
How the Company Makes Money
Kuros Biosciences makes money primarily by selling its bone graft substitute products used in surgical bone repair and spinal fusion procedures. Revenue is generated from product sales to healthcare providers and/or via commercial partners/distrib...
Kuros Biosciences Earnings Call Summary
Earnings Call Date:Aug 13, 2026
(Q2-2026)
| % Change Since: |
Next Earnings Date:Mar 03, 2027
Earnings Call Sentiment Positive
The call communicated a strong set of operational and financial achievements (robust +45% H1 revenue growth, first sustained half‑year profitability with CHF 12.5M adjusted EBITDA and CHF 4.4M net profit, improving gross margins, strong clinical evidence and a clear midterm revenue/margin target). These positives are tempered by planned near‑term investments and transformation costs, expected dilution from the U.S. manufacturing ramp, lumpiness in international revenue, and working capital accumulation that creates short-term liquidity sensitivity. On balance, the transformational investments are framed as deliberate and the company maintained conservative near-term guidance while presenting a credible path to >20% adjusted EBITDA by 2028, so the overall tone is confident with manageable near-term risks.Positive Updates
Strong H1 2026 Revenue Growth
Total medical device sales of $92.4M in H1 2026, representing +45% year-over-year growth vs H1 2025; direct MagnetOs sales grew +46%, and revenue has increased ~566% since H1 2023 (demonstrating rapid scale).
Negative Updates
H2 Caution and Guidance Unchanged
Despite +45% H1 growth, company kept 2026 guidance at ~35% growth (management cited typical cadence and will revisit in Q3), implying a moderation in H2 growth relative to H1 acceleration.
Read all updates
Q2-2026 Updates
Positive
Negative
Strong H1 2026 Revenue Growth
Total medical device sales of $92.4M in H1 2026, representing +45% year-over-year growth vs H1 2025; direct MagnetOs sales grew +46%, and revenue has increased ~566% since H1 2023 (demonstrating rapid scale).
Read all positive updates
Company Guidance
Management reiterated mid‑term guidance that revenue should more than double from CHF 146m in 2025 to CHF 300–330m by 2028, with 2026 growth targeted at ~35% and a path to an adjusted EBITDA margin above 20% by 2028 (management cites >6 percentage points of functional cost‑ratio improvement from unit‑cost optimization, commercial operating leverage, targeted R&D and G&A efficiencies). In H1 they reported medical device sales of $92.4m (up 45% YoY), adjusted EBITDA CHF 12.5m (13.6% margin), net profit CHF 4.4m, EPS CHF 0.11 (vs –CHF 0.05 prior year), cash CHF 9.7m plus receivables CHF 44.4m (CHF 54.2m total), an undrawn CHF 12.4m bridge facility, distributor reach +34% YoY, ~4x market‑share increase since 2023, >150,000 patients treated, three Level‑1 trials at 83%/49%/14% enrollment (PROOF/PRECISE/ASTRA), U.S. manufacturing expected live H2 2026, and planned CapEx roughly CHF 11–12m (U.S.), CHF 2–3m (Netherlands) and ~CHF 1m IT (total ~CHF 15–16m).Kuros Biosciences Financial Statement Overview
Summary
Income Statement
74
Positive
Balance Sheet
82
Very Positive
Cash Flow
46
Neutral
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 138.71M | 121.30M | 75.56M | 33.56M | 17.99M | 13.81M |
| Gross Profit | 118.30M | 104.79M | 62.03M | 23.94M | 10.77M | 10.07M |
| EBITDA | 11.55M | 10.01M | -537.00K | -6.84M | -8.84M | -5.29M |
| Net Income | 7.12M | 2.12M | -3.72M | -13.73M | -14.60M | -7.54M |
Balance Sheet | ||||||
| Total Assets | 120.15M | 107.21M | 84.54M | 71.46M | 82.95M | 91.34M |
| Cash, Cash Equivalents and Short-Term Investments | 7.85M | 15.66M | 17.46M | 14.21M | 24.07M | 28.62M |
| Total Debt | 11.01M | 3.94M | 1.79M | 2.14M | 1.91M | 8.93M |
| Total Liabilities | 48.15M | 40.28M | 25.79M | 14.75M | 14.09M | 14.36M |
| Stockholders Equity | 72.00M | 66.93M | 58.75M | 56.71M | 68.86M | 76.98M |
Cash Flow | ||||||
| Free Cash Flow | -6.61M | -2.40M | 2.03M | -9.17M | -7.75M | -5.83M |
| Operating Cash Flow | -292.91K | -377.87K | 3.14M | -8.84M | -7.35M | -5.45M |
| Investing Cash Flow | -6.32M | -2.03M | -1.11M | -326.00K | -400.00K | -374.00K |
| Financing Cash Flow | 123.57K | 1.17M | 1.34M | -171.00K | 3.22M | 6.08M |
Kuros Biosciences Technical Analysis
Positive
21.42
Price Trends
18.85
Positive
19.78
Positive
21.84
Negative
Market Momentum
0.40
Negative
55.98
Neutral
78.33
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CH:KURN, the sentiment is Positive. The current price of 21.42 is above the 20-day moving average (MA) of 18.76, above the 50-day MA of 18.85, and below the 200-day MA of 21.84, indicating a neutral trend. The MACD of 0.40 indicates Negative momentum. The RSI at 55.98 is Neutral, neither overbought nor oversold. The STOCH value of 78.33 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CH:KURN.
Kuros Biosciences Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
74 Outperform | CHF6.25B | 41.88 | 10.27% | 1.08% | 4.51% | 11.05% | |
73 Outperform | CHF888.40M | 16.95 | ― | 8.99% | 4.74% | -28.96% | |
67 Neutral | CHF43.33B | -412.86 | ― | 0.79% | -10.77% | -114.77% | |
63 Neutral | CHF791.16M | 109.94 | 10.24% | ― | 40.91% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | CHF127.18M | -2.32 | -67.67% | ― | -100.00% | 24.46% | |
45 Neutral | CHF1.22B | -3.47 | ― | 86.75% | -8.06% | -87.00% |
* Healthcare Sector Average
CH:KURN
Kuros Biosciences
19.90
-9.24
-31.71%
CH:MOLN
Molecular Partners AG
3.15
0.24
8.25%
CH:LONN
Lonza Group Ltd
635.80
71.52
12.67%
CH:BSLN
Basilea Pharmaceutica
72.20
25.45
54.44%
CH:IDIA
Idorsia Ltd
4.55
1.17
34.67%
CH:BANB
Bachem Holding AG
83.35
26.04
45.43%
Kuros Biosciences Corporate Events
Kuros Biosciences Lifts 2026 Guidance on Strong Sales and New U.S. Production
Oct 15, 2026
Kuros Biosciences reported a robust nine‑month performance for 2026, with total medical device sales rising 40% year‑on‑year to USD 141.8 million and group EBITDA up 81% to USD 13.5 million. Adjusted EBITDA reached USD 20.6 milli...
Kuros Biosciences Posts Strong H1 Growth as MagnetOs Gains Orthobiologics Share
Aug 13, 2026
Kuros Biosciences reported a 45% year-on-year increase in H1 2026 medical device sales to USD 92.4 million, with adjusted EBITDA up 61% and the group swinging from a loss to a USD 4.4 million net profit. Despite higher sales, RD and administrative...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.